Tolvaptan can improve clinical course in responders validation analysis for the definition of responsiveness by urine volume

International Heart Journal

Volumn 54, Issue 6, 2013, Pages 377-381

  Imamura, Teruhiko ^a   Kinugawa, Koichiro ^a   Minatsuki, Shun ^a   Muraoka, Hironori ^a   Kato, Naoko ^a   Inaba, Toshiro ^a   Maki, Hisataka ^a   Hatano, Masaru ^a   Yao, Atsushi ^a   Komuro, Issei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Heart failure; Urine osmolality; Vasopressin

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; CREATININE; FUROSEMIDE; NITROGEN; SPIRONOLACTONE; TOLVAPTAN; TRICHLORMETHIAZIDE; UREA;

ADOLESCENT; ADULT; AGED; ARTICLE; CONGESTIVE HEART FAILURE; CREATININE BLOOD LEVEL; DRUG RESPONSE; FEMALE; FLUID RETENTION; HEART FAILURE; HEART FAILURE SYMPTOM SCORE; HOSPITAL PATIENT; HUMAN; HYPONATREMIA; LUNG CONGESTION; MAJOR CLINICAL STUDY; MALE; NEW YORK HEART ASSOCIATION CLASS; PERIPHERAL EDEMA; PRIORITY JOURNAL; SCORING SYSTEM; UREA NITROGEN BLOOD LEVEL; URINE OSMOLALITY; URINE VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENZAZEPINES; DIURETICS; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; RECEPTORS, VASOPRESSIN; URINE; YOUNG ADULT;

EID: 84889052131     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.54.377     Document Type: Article

References (17)

1. Inomata T, Izumi T, Matsuzaki M, Hori M, Hirayama A. Phase III clinical pharmacology study of tolvaptan. Cardiovasc Drugs Ther 2011; 25: 57-65.
2. Matsuzaki M, Hori M, Izumi T, Fukunami M. Effcacy and safety of tolvaptan in heart failure patients with volume overload despite the standard treatment with conventional diuretics: a phase III, randomized, double-blind, placebo-controlled study (QUEST study). Cardiovasc Drugs Ther 2011; 25: 33-45.
3. Robertson GL. Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011; 7: 151-161. (Review)
4. Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355: 2099-2112.
5. Udelson JE, Orlandi C, Ouyang J, et al. Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008; 52: 1540-1545.
6. Konstam MA, Gheorghiade M, Burnett JC Jr, et al. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007; 297: 1319-1331.
7. Watanabe K, Dohi K, Sugimoto T, et al. Short-term effects of low-dose tolvaptan on hemodynamic parameters in patients with chronic heart failure. J Cardiol 2012; 60: 462-469.
8. Matsue Y, Suzuki M, Seya M, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol 2013; 61: 169-174.
9. Imamura T, Kinugawa K, Shiga T, et al. Correction of hypona-tremia by tolvaptan before left ventricular assist device implantation. Int Heart J 2012; 53: 391-393.
10. Imamura T, Kinugawa K, Kato N, et al. Successful conversion from thiazide to tolvaptan in a patient with stage d heart failure and chronic kidney disease before heart transplantation. Int Heart J 2013; 54: 48-50.
11. Imamura T, Kinugawa K, Shiga T, et al. Novel criteria of urine os-molality effectively predict response to tolvaptan in decompensat-ed heart failure patients -- association between non-responders and chronic kidney disease. Circ J 2013; 77: 397-404.
12. Imamura T, Kinugawa K, Minatsuki S, et al. Urine osmolality estimated using urine urea nitrogen, sodium and creatinine can effectively predict response to tolvaptan in decompensated heart failure patients. Circ J 2013; 77: 1208-1213.
13. Garin O, Ferrer M, Pont A, et al. Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses. Qual Life Res 2009; 18: 71-85. (Review)
14. Kato N, Kinugawa K, Seki S, et al. Quality of life as an independent predictor for cardiac events and death in patients with heart failure. Circ J 2011; 75: 1661-1669.
15. Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21: 705-712.
16. Yang B, Bankir L. Urea and urine concentrating ability: new insights from studies in mice. Am J Physiol Renal Physiol 2005; 288: 881-896. (Review)
17. Hillege HL, Girbes AR, De Kam PJ, et al. Renal function, neuro-hormonal activation, and survival in patients with chronic heart failure. Circulation 2000; 102: 203-210.